Exhibit 10.2


 


Execution Version


 


BIOSCRIP,
INC.


 


Director
NOMINATION Agreement


 


THIS Director
NOMINATION Agreement (this “Agreement”) is made and entered into as of August 6, 2019 by and among BioScrip,
Inc., a Delaware corporation (the “Company”), and HC Group Holdings I, LLC, a Delaware limited liability company
(“Investor”). This Agreement will become effective (the “Effective Date”) only upon the issuance
of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at the First Merger Effective
Time, as such term is defined under that certain Agreement and Plan of Merger, dated as of March 14, 2019, by and among the Company,
Investor, HC Group Holdings II, Inc., a Delaware corporation, HC Group Holdings III, Inc., a Delaware corporation, Beta Sub, Inc.,
a Delaware corporation and Beta Sub, LLC, a Delaware corporation (as amended or modified, the “Merger Agreement”).


 


In consideration of
the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, each of the parties to this Agreement agrees as follows:


 


1.           Board
Nomination Rights.


 


(a)          From
the Effective Date until the date that Investor and its Affiliates (as defined below) cease to Beneficially Own shares of Common
Stock representing at least 10% of the total voting power of the then outstanding Common Stock, at every meeting (“Election
Meeting”) of the board of directors of the Company (the “Board”), or a committee thereof, for which
directors of the Company are appointed by the Board or are nominated to stand for election by stockholders of the Company, Investor
shall have the right to nominate for election to the Board, or appoint to fill a vacancy on the Board, as applicable, in each case
in accordance with the Company’s Amended and Restated Bylaws (the “Bylaws”), a number of representatives
equal to the product obtained by multiplying (a) the percentage of the total voting power of the then outstanding Common Stock
then Beneficially Owned by Investor and its Affiliates (the “Investor Voting Control”) and (b) the authorized
number of directors on the Board, including any vacancies, with such product rounded up to the nearest whole number in all cases
(such persons, the “Nominees”). Notwithstanding the foregoing, the number of Nominees at the Effective Date
shall be eight, nothing in this Agreement shall be deemed to modify Section 1.6 of the Merger Agreement and in the event of a conflict
between the provision of this Agreement and the Merger Agreement, the Merger Agreement shall control. “Beneficially Own”
shall have the meaning set forth in Section 13d-3 of the Securities Exchange Act of 1934, as amended. “Affiliate” of
any person shall mean any other person controlled by, controlling or under common control with such person; where “control”
(including, with its correlative meanings, “controlling,” “controlled by” and “under common control
with”) means possession, directly or indirectly, of power to direct or cause the direction of management or policies (whether
through ownership of securities, by contract or otherwise).


 




     


     


    

 


(b)          No
reduction in the number of shares of Common Stock over which Investor retains voting control shall shorten the term of any incumbent
director. At the Effective Date, pursuant to the Merger Agreement, the Board shall be comprised of 10 members and the initial Nominees
shall be Timothy Sullivan, Elizabeth Q. Betten, Nitan Sahney, Harry M. Jansen Kraemer, Jr., John J. Arlotta, John Rademacher, Mark
Vainisi and Alan Nielsen.


 


(c)          In
the event that any Nominee shall cease to serve as a director prior to the end of a term for which it has been duly elected because
of such Nominee’s removal, death, disability, disqualification or resignation from the Board, Investor shall be entitled
to promptly designate such person’s successor in accordance with this Agreement (regardless of the level of Investor Voting
Control at the time of such designation, unless the Investor Voting Control at such time is less than 10% of the total voting power
of the then outstanding Common Stock, in which case the Investor shall have no right to designate a replacement Nominee) and the
Board shall use reasonable best efforts to promptly fill the vacancy with such successor Nominee; it being understood that any
such designee shall serve the remainder of the term of the director whom such designee replaces.


 


(d)          If
a Nominee withdraws as a nominee prior to an Election Meeting or is otherwise unable to stand for election for any other reason
(whether by reason of such person’s death, disability, disqualification or otherwise), Investor shall be entitled to designate
promptly a replacement Nominee prior to such Election Meeting.


 


(e)          If
the size of the Board is expanded, Investor shall be entitled to nominate a number of Nominees to fill the newly created vacancies
such that the total number of Nominees serving on the Board following such expansion will be equal to that number of Nominees that
Investor would be entitled to nominate in accordance with Section 1(a) if such expansion occurred immediately prior to an
Election Meeting, and the Board shall appoint such Nominees to the Board.


 


(f)           The
Company shall use its reasonable best efforts to maintain in effect at all times directors and officers indemnity insurance coverage
on customary and reasonable terms, and the Company’s Amended and Restated Certificate of Incorporation and Bylaws (each as
may be further amended, supplemented or waived in accordance with its terms) shall at all times provide for indemnification, exculpation
and advancement of expenses to the fullest extent permitted under applicable law.


 


(g)          At
such time as the Company ceases to be a “controlled company” and is required by applicable law or the Nasdaq Stock
Market (the “Exchange”) listing standards to have a majority of the Board comprised of “independent directors”
(subject in each case to any applicable phase-in periods), Investor’s Nominees shall include a number of persons that qualify
as “independent directors” under applicable law and the Nasdaq Stock Market (the “Exchange”) listing
standards such that, together with any other “independent directors” then serving on the Board that are not Nominees,
the Board is comprised of a majority of “independent directors”; provided, however, that nothing in this Section 1(g)
shall require the Company to cause John C. Rademacher (or his successor as Chief Executive Officer) to resign from the Board and/or
prevent the Company from nominating John C. Rademacher or the then current Chief Executive Officer for re-election to the Board
after the Company ceases to qualify as a “controlled company” under the rules of the Exchange if serving as Chief Executive
Officer at such time.


 




    	 	2	 



     


    

 


2.          Company
Obligations. The Company agrees to use its reasonable best efforts to ensure that prior to the date that Investor and its Affiliates
cease to Beneficially Own shares of Common Stock representing at least 10% of the total voting power of the then outstanding Common
Stock, (i) each Nominee is included in the Board’s slate of nominees to the stockholders (the “Board’s Slate”)
for each election of directors; and (ii) each Nominee designated by Investor in accordance with this Agreement is included in the
proxy statement prepared by management of the Company in connection with soliciting proxies for every Election Meeting (each, a
“Director Election Proxy Statement”), and at every adjournment or postponement thereof, and on every action
or approval by written consent of the stockholders of the Company or the Board with respect to the election of members of the Board.
The calculation of the number of Nominees that Investor is entitled to nominate to the Board’s Slate for any election of
directors shall be based on the Investor Voting Control immediately prior to the mailing to shareholders of the Director Election
Proxy Statement relating to such election (or, if earlier, the filing of the definitive Director Election Proxy Statement with
the U.S. Securities and Exchange Commission). Unless Investor notifies the Company otherwise prior to the mailing to shareholders
of the Director Election Proxy Statement relating to an election of directors, the Nominees for such election shall be presumed
to be the same Nominees currently serving on the Board, and no further action shall be required of Investor for the Board to include
such Nominees on the Board’s Slate; provided, that, in the event Investor is no longer entitled to nominate the full number
of Nominees then serving on the Board, Investor shall provide advance written notice to the Company, of which currently servicing
Nominee(s) shall be excluded from the Board Slate, and of any other changes to the list of Nominees. If Investor fails to provide
such notice prior to the mailing to shareholders of the Director Election Proxy Statement relating to such election (or, if earlier,
the filing of the definitive Director Election Proxy Statement with the U.S. Securities and Exchange Commission), a majority of
the independent directors then serving on the Board shall determine which of the Nominees of the Investor then serving on the Board
will be included in the Board’s Slate. Furthermore, the Company agrees for so long as the Company qualifies as a “controlled
company” under the rules of the Exchange the Company will elect to be a “controlled company” for purposes of
the Exchange and will disclose in its annual meeting proxy statement that it is a “controlled company” and the basis
for that determination. The Company and Investor acknowledge and agree that, as of the Effective Date, the Company will be a “controlled
company.”


 


3.          Committees.
From and after the Effective Date hereof until such time as Investor and its Affiliates cease to Beneficially Own shares of Common
Stock representing at least 10% of the total voting power of the then outstanding Common Stock, Investor shall have the right to
designate a number of members of each committee of the Board equal to the product obtained by multiplying (a) the Investor Voting
Control and (b) the number of positions, including any vacancies, on the applicable committee with such product rounded up to the
nearest whole number, provided that any such designee shall be a director and shall be eligible to serve on the applicable committee
under applicable law or listing standards of the Exchange, including any applicable independence requirements (subject in each
case to any applicable exceptions for “controlled companies”). Any additional members shall be determined by the Board.
Nominees designated to serve on a Board committee shall have the right to remain on such committee until the next election of directors,
regardless of the level of Investor Voting Control following such designation. Unless Investor notifies the Company otherwise prior
to the time the Board takes action to change the composition of a Board committee, and to the extent Investor has the requisite
Investor Voting Control to nominate a Board committee member at the time the Board takes action to change the composition of any
such Board committee, any Nominee currently designated by the Investor to serve on a committee shall be presumed to be re-designated
for such committee.


 




    	 	3	 



     


    

 


4.          Obligations
of Investor. As a condition to any Nominee’s nomination for election or designation to fill a vacancy as a director of
the Company hereunder, Investor shall (or shall cause the Nominee) promptly upon the request of the Company from time to time and
on or prior to the date specified by the Company in such request, provide to the Company (i) such information as is required to
be disclosed in a Director Election Proxy Statement under applicable law, (ii) an executed consent from the Nominee to be named
as a nominee in the Company’s Director Election Proxy Statement for the applicable stockholder meeting and to serve as a
director if so elected, and (iii) such other information as the Company may reasonably and customarily request.


 


5.          Amendment
and Waiver. Any provision of this Agreement may be amended or waived if, but only if, such amendment or waiver is in writing
and is signed, in the case of an amendment, by the Company and Investor, or in the case of a waiver, by the party against whom
the waiver is to be effective. No failure or delay by any party in exercising any right, power or privilege hereunder shall operate
as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise
of any other right, power or privilege. Investor shall not be obligated to nominate all (or any) of the Nominees it is entitled
to nominate pursuant to this Agreement for any election of directors but the failure to do so shall not constitute a waiver of
its rights hereunder with respect to future elections; provided, however, that in the event Investor fails to nominate
all (or any) of the Nominees it is entitled to nominate pursuant to this Agreement prior to the mailing to shareholders of the
Director Election Proxy Statement relating to such election (or, if earlier, the filing of the definitive Director Election Proxy
Statement with the U.S. Securities and Exchange Commission), the Governance, Compliance and Nominating Committee of the Board shall
be entitled to nominate individuals in lieu of such Nominees for inclusion in the Board’s Slate and the applicable Director
Election Proxy Statement with respect to the election for which such failure occurred and Investor shall be deemed to have waived
its rights hereunder with respect to such election. The rights and remedies herein provided shall be cumulative and not exclusive
of any rights or remedies provided by law.


 


6.         Termination.
This Agreement shall terminate automatically on the date that Investor and its Affiliates, collectively, cease to Beneficially
Own shares of Common Stock representing at least 10% of the total voting power of the then outstanding Common Stock.


 


7.          Benefit
of Parties. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective
permitted successors and assigns. Notwithstanding the foregoing, the Company may not assign any of its rights or obligations hereunder
without the prior written consent of Investor. Nothing herein contained shall confer or is intended to confer on any third party
or entity that is not a party to this Agreement any rights under this Agreement.


 




    	 	4	 



     


    

 


8.          Headings.
Headings are for ease of reference only and shall not form a part of this Agreement.


 


9.          Governing
Law. This Agreement shall be construed in accordance with and governed by the law of the State of Delaware without giving effect
to the principles of conflicts of laws thereof.


 


10.         Jurisdiction.
Any suit, action or proceeding seeking to enforce any provision of, or based on any matter arising out of or in connection with,
this Agreement may be brought against any of the parties in any federal court located in the State of Delaware or any Delaware
state court, and each of the parties hereby consents to the exclusive jurisdiction of such court (and of the appropriate appellate
courts) in any such suit, action or proceeding and waives any objection to venue laid therein. Process in any such suit, action
or proceeding may be served on any party anywhere in the world, whether within or without the jurisdiction of any such court. Without
limiting the foregoing, each of the parties agrees that service of process upon such party at the address referred to in Section
17, together with written notice of such service to such party, shall be deemed effective service of process upon such party.


 


11.         WAIVER
OF JURY TRIAL. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING
ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT.


 


12.         Entire
Agreement. With the exception of the Merger Agreement, this Agreement constitutes the entire agreement among the parties with
respect to the subject matter hereof and supersedes all prior agreements (other than the Merger Agreement), understandings and
negotiations, both written and oral among the parties with respect to the subject matter hereof.


 


13.         Counterparts;
Effectiveness. This Agreement may be signed in any number of counterparts, each of which shall be deemed an original. This
Agreement shall become effective when each party shall have received a counterpart hereof signed by each of the other parties.
An executed copy or counterpart hereof delivered by facsimile shall be deemed an original instrument.


 


14.         Severability.
If any provision of this Agreement or the application thereof to any person or circumstance shall be invalid or unenforceable to
any extent, the remainder of this Agreement and the application of such provisions to other persons or circumstances shall not
be affected thereby and shall be enforced to the greatest extent permitted by law.


 


15.         Further
Assurances. Each of the parties hereto shall execute and deliver such further instruments and do such further acts and things
as may be reasonably required to carry out the intent and purpose of this Agreement.


 




    	 	5	 



     


    

 


16.         Specific
Performance. Each of the parties hereto agrees that irreparable damage may occur if any provision of this Agreement were not
performed in accordance with the terms hereof and that the parties shall be entitled to seek an injunction or injunctions to prevent
breaches of this Agreement or to enforce specifically the performance of the terms and provisions hereof in any federal or state
court located in the State of Delaware, in addition to any other remedy to which they are entitled at law or in equity.


 


17.         Notices.
All notices, requests and other communications to any party or to the Company shall be in writing (including telecopy, e-mail or
similar writing) and shall be given,


 


If to the Company:


 


BioScrip, Inc.

1600 Broadway, Suite 700

Denver, CO 80202

Attention: General Counsel


 


With a copy to (which shall not constitute notice):


 


Gibson, Dunn &
Crutcher, LLP


200 Park Avenue


New York, NY 10166


Attention: Sean P.
Griffiths


 


If to any member
of Investor or any Nominee:


 


c/o HC Group Holdings
I, LLC


c/o Madison Dearborn
Partners, L.L.C.


70 W. Madison St.


Suite 4600


Chicago, Illinois 60602


Attention: General
Counsel


 


With a copy to (which
shall not constitute notice):


 


Kirkland & Ellis
LLP


300 N. LaSalle


Chicago, IL 60654


Attention: Sanford
E. Perl, P.C.


    Mark A. Fennell,
P.C.


 


or to such other address or telecopier
number as such party or the Company may hereafter specify for the purpose by notice to the other parties and the Company. Each
such notice, request or other communication shall be effective when delivered at the address specified in this Section 17
during regular business hours.


 




    	 	6	 



     


    

 


18.         Enforcement.
Each of the parties hereto covenant and agree that the disinterested members of the Board have the right to enforce, waive or take
any other action with respect to this Agreement on behalf of the Company.


 


*         *         *         *         *


 




    	 	7	 



     


    

 


IN WITNESS WHEREOF, the parties hereto
have executed this Agreement on the date first above written.


 


	 	BIOSCRIP, INC.
	 	 	 
	 	By:	/s/ Daniel Greenleaf
	 	 	Name: Daniel E. Greenleaf
	 	 	Title: President
	 	 	 
	 	HC GROUP HOLDINGS I, LLC
	 	 	 
	 	By:	/s/ Clifford Berman
	 	 	Name: Clifford Berman 
	 	 	Title: Corporate Secretary


 


[BioScrip - Director Nomination Agreement]